Grass Pollen Allergy - Pipeline Review, H1 2016

 Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Grass Pollen Allergy Overview 7
Therapeutics Development 8
Pipeline Products for Grass Pollen Allergy - Overview 8
Grass Pollen Allergy - Therapeutics under Development by Companies 9
Grass Pollen Allergy - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Grass Pollen Allergy - Products under Development by Companies 13
Grass Pollen Allergy - Companies Involved in Therapeutics Development 14
ALK-Abello A/S 14
Allergy Therapeutics Plc 15
Anergis SA 16
Biomay AG 17
Circassia Pharmaceuticals Plc 18
HAL Allergy BV 19
Roxall Medizin GmbH 20
Shionogi & Co., Ltd. 21
Grass Pollen Allergy - Therapeutics Assessment 22
Assessment by Monotherapy Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
AllerG - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Allergen for Grass Allergy - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Allergen for Pollen Grass Allergy Induced Allergic Rhinitis and Rhinoconjunctivitis - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Allergen for Seasonal Grass Pollen Induced Allergic Rhinitis and Rhino-Conjunctivitis - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
asapiprant - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
BM-32 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
clustoid wiesenlieschgras - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Pollinex Quattro Grass - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
standardized grass pollen [timothy (Phleum pratense)] allergen extract - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Vaccine for Grass-Induced Rhinoconjunctivitis and Asthma - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Grass Pollen Allergy - Recent Pipeline Updates 43
Grass Pollen Allergy - Dormant Projects 50
Grass Pollen Allergy - Product Development Milestones 51
Featured News & Press Releases 51
Feb 18, 2016: Allergy Therapeutics Announces Patient enrolment completed in US Phase IIb study of GrassMATAMPL 51
Jan 14, 2016: ALK announces top-line results from the five-year landmark GRAZAX Asthma Prevention trial in children 51
Jun 03, 2015: Positive phase IIb data on BM32, Biomay's innovative grass pollen allergy vaccine will be reported in hot topic session at major international scientific conference. 52
Jan 28, 2015: Biomay reports positive Phase IIb data with the innovative 3rd generation grass pollen allergy vaccine BM32 53
Apr 14, 2014: ALK announces FDA approval for Merck's grass sublingual allergy immunotherapy tablet GRASTEK 54
Feb 18, 2014: Health Canada approves submission of CTA to progress ultra-short course Pollinex Quattro Grass efficacy study 54
Feb 03, 2014: Merck Announces Canadian Approval of GRASTEK (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet) 55
Dec 16, 2013: Biomay AG successfully completes interim analysis of phase IIb study with the innovative 3rd generation grass pollen allergy vaccine BM32 55
Dec 12, 2013: FDA Advisory Committee meeting unanimously recommends approval of GRASTEK 56
Dec 10, 2013: ALK announces posting of briefing documents for FDA Advisory Committee meeting on the grass sublingual AIT tablet 56
Appendix 58
Methodology 58
Coverage 58
Secondary Research 58
Primary Research 58
Expert Panel Validation 58
Contact Us 58
Disclaimer 59

List of Tables

Number of Products under Development for Grass Pollen Allergy, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Grass Pollen Allergy - Pipeline by ALK-Abello A/S, H1 2016 14
Grass Pollen Allergy - Pipeline by Allergy Therapeutics Plc, H1 2016 15
Grass Pollen Allergy - Pipeline by Anergis SA, H1 2016 16
Grass Pollen Allergy - Pipeline by Biomay AG, H1 2016 17
Grass Pollen Allergy - Pipeline by Circassia Pharmaceuticals Plc, H1 2016 18
Grass Pollen Allergy - Pipeline by HAL Allergy BV, H1 2016 19
Grass Pollen Allergy - Pipeline by Roxall Medizin GmbH, H1 2016 20
Grass Pollen Allergy - Pipeline by Shionogi & Co., Ltd., H1 2016 21
Assessment by Monotherapy Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Grass Pollen Allergy Therapeutics - Recent Pipeline Updates, H1 2016 43
Grass Pollen Allergy - Dormant Projects, H1 2016 50 

To request a free sample copy of this report, please complete the form below.

Enter captcha code*

We never share your personal data. Privacy policy